Endoscopic and Surgical Treatment Outcomes of Colitis-associated Advanced Neoplasia: a Multicenter Cohort Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Enrollment
- 189
- Locations
- 1
- Primary Endpoint
- Synchronous
Study Overview
Brief Summary
In this study, we aimed to (1) compare cumulative incidences of synchronous and metachronous colorectal neoplasia as well as mortality following AN in CD and UC patients who underwent proctocolectomy, (sub)total colectomy, partial colectomy or endoscopic resection, and (2) to determine factors associated with AN treatment choice.
Detailed Description
In this retrospective multicenter cohort study, using PALGA (the Dutch nationwide pathology databank), partial colectomy yielded a similar metachronous neoplasia risk compared to (sub)total colectomy after treatment of advanced neoplasia in inflammatory bowel disease. High metachronous neoplasia rates after endoscopic resection underline the importance of strict subsequent endoscopic surveillance.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •IBD (ulcerative colitis (UC), CD or IBD-unclassified (IBD-U))
- •Histological diagnosis of colorectal AN
- •Available treatment data
Exclusion Criteria
- •Familial CRC syndrome
- •AN prior to IBD diagnosis
Outcomes
Primary Outcomes
Synchronous
Time Frame: up to 6 months
defined as co-existence of two or more neoplastic colorectal lesions detected in the initial resection specimen or up to 6 months after treatment of the index lesion, categorized in (a) any neoplasia (independent of grade) and (b) only AN
Metachronous (advanced) neoplasia
Time Frame: up to 30 years
defined as colorectal neoplasia detected \>6 months after treatment of index AN, categorized in (a) any neoplasia (independent of grade) and (b) only AN, including the impact of IBD type
Secondary Outcomes
- All-cause mortality(up to 30 years)
- Associations with treatment choice(up to 30 years)